Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

NCT02662296 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Low enrollment

Conditions

Prolymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Idelalisib

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]